Molecular target
Synaptic Vesicle Glycoprotein 2A
Presynaptic vesicle protein involved in vesicle fusion and neurotransmitter release. Bound by levetiracetam — the basis for its broad-spectrum anti-seizure action with a relatively clean side-effect profile.
Educational use only. This page summarizes published research and traditional-use records for educational purposes. It does not diagnose, treat, cure, or prevent any disease. Do not start, stop, or change medications based on this information. Discuss any decisions about therapies — pharmaceutical or botanical — with a qualified clinician who knows your medical history.
No PHI / HIPAA notice: Do not share Protected Health Information (PHI) of any patient on this site — including names, dates of birth, addresses, MRNs, or any identifying information. Use abstract case framing only. Sharing PHI with non-covered entities risks HIPAA violation regardless of platform capability.
Pharmaceutical agents
Drugs that act on Synaptic Vesicle Glycoprotein 2A
These medications have Synaptic Vesicle Glycoprotein 2A among their molecular targets. Sharing a target is a mechanistic relationship — it does not make any plant below an alternative to, or substitute for, these drugs.